Juan Luis
Gómez Sirvent
Investigador en el periodo 1992-2022
Hospital San Pedro
Logroño, EspañaPublicaciones en colaboración con investigadores/as de Hospital San Pedro (19)
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
2020
-
Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey
Evidence-based mental health, Vol. 23, Núm. 3, pp. 91-99
-
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 5, pp. 1294-1300
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700
2017
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Reproductive history before and after HIV diagnosis: A cross-sectional study in HIV-positive women in Spain
Medicine (United States), Vol. 96, Núm. 5
2015
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
-
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 16, Núm. 1, pp. 43-48
-
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5
2014
-
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 9
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2013
-
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 14, Núm. 5, pp. 204-215
2010
-
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study
The Lancet, Vol. 376, Núm. 9738, pp. 340-345
2009
-
Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality
Current HIV Research, Vol. 7, Núm. 2, pp. 224-230
-
Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART
Current HIV Research, Vol. 7, Núm. 6, pp. 612-619
2008
-
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status
International Journal of Tuberculosis and Lung Disease, Vol. 12, Núm. 12, pp. 1393-1400
-
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy
Current HIV Research, Vol. 6, Núm. 2, pp. 100-107